Visiox is a biopharmaceutical company developing ophthalmic therapeutics, including Omlonti® for ocular hypertension and PDP-716, a once-daily brimonidine formulation, utilizing proprietary extended-release technologies. The company addresses the need for effective treatment options in prevalent eye diseases, enhancing patient outcomes and physician satisfaction.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with ocular hypertension and open-angle glaucoma require more effective and convenient treatment options to lower intraocular pressure (IOP). Current treatments may not provide sufficient IOP reduction or may require frequent administration, impacting patient compliance and outcomes. Additionally, post-surgical inflammation and pain management in the eye can be challenging, requiring effective topical treatments.
Solution
Visiox is a biopharmaceutical company focused on developing and commercializing ophthalmic therapeutics that address prevalent eye diseases. The company's lead product, Omlonti, is an EP2 receptor agonist that reduces elevated IOP in patients with open-angle glaucoma or ocular hypertension. Visiox is also developing PDP-716, a once-daily brimonidine formulation for ocular hypertension and open-angle glaucoma, utilizing TearAct fine resin technology for extended release. Furthermore, SDN-037, a twice-daily topical difluprednate for post-surgical inflammation and pain, leverages the TJM micellar platform for enhanced drug delivery.
Target Audience
The primary target audience includes patients with ocular hypertension, open-angle glaucoma, and those experiencing post-surgical inflammation and pain in the eye, as well as ophthalmologists and eye care professionals seeking advanced treatment options.
Features
- Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%: EP2 receptor agonist for IOP reduction in open-angle glaucoma and ocular hypertension
- PDP-716: Once-daily brimonidine formulation for ocular hypertension and open-angle glaucoma, utilizing TearAct fine resin technology
- SDN-037: Twice-daily topical difluprednate for post-surgical inflammation and pain, utilizing the TJM micellar platform
- Proprietary extended-release technologies with patent protection through at least 2036